Parkinson's Disease Trial, By Invitation NCT06980935 Sponsor: Ruijin Hospital Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, By Invitation

NCT06980935
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with primary Parkinson's disease according to MDS (Movement Disorder Society) criteria.
  • People whose Parkinson's disease is at a relatively early stage (Hoehn & Yahr stage below 3, meaning symptoms are not yet severely limiting balance or mobility).
  • People whose Parkinson's disease medications have not changed in the four weeks before the trial, and whose medication doses will remain the same throughout the study.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have other neurological conditions that could affect the study results, such as a history of traumatic brain injury.
  • People who have a history of taking antipsychotic medications, antidepressants, or medications that affect dopamine, other than standard Parkinson's disease drugs.
  • People who have metal devices in their head or chest, such as deep brain stimulators or pacemakers.
  • People whose vital signs (such as heart rate, blood pressure, or breathing) are not stable.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
14 April 2025
Est. completion
15 May 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇳 China

Primary endpoints

MDS-UPDRS-Ⅲ scores

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov